These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38454800)

  • 1. SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice.
    Zeng L; Li J; Gao F; Song Y; Wei L; Qu N; Chen S; Zhao X; Lei Z; Cao W; Chen L; Jiang H
    J Cell Mol Med; 2024 Mar; 28(6):e18176. PubMed ID: 38454800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
    Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
    Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Comparation of Renal Anti-Senescence Effects and Blood Metabolites between Dapagliflozin and Metformin in Non-Diabetes Environment.
    Zeng L; Chen L; Gao F; Li J; Song Y; Wei L; Qu N; Li Y; Jiang H
    Adv Biol (Weinh); 2023 Oct; 7(10):e2300199. PubMed ID: 37688360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
    Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
    Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
    Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
    Ke Q; Shi C; Lv Y; Wang L; Luo J; Jiang L; Yang J; Zhou Y
    FASEB J; 2022 Jan; 36(1):e22078. PubMed ID: 34918381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells.
    Pirklbauer M; Schupart R; Fuchs L; Staudinger P; Corazza U; Sallaberger S; Leierer J; Mayer G; Schramek H
    Am J Physiol Renal Physiol; 2019 Mar; 316(3):F449-F462. PubMed ID: 30539648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation.
    Kim MN; Moon JH; Cho YM
    Diabetes Obes Metab; 2021 Nov; 23(11):2561-2571. PubMed ID: 34318973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model.
    Pan X; Phanish MK; Baines DL; Dockrell MEC
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34003249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin, SGLT
    Abbas NAT; El Salem A; Awad MM
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Dec; 391(12):1347-1360. PubMed ID: 30090949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
    Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
    Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.